BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson Sells 4,148 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 4,148 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total transaction of $149,991.68. Following the completion of the sale, the chief financial officer now owns 102,464 shares of the company’s stock, valued at $3,705,098.24. The trade was a 3.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $36.29 on Thursday. The company’s 50-day moving average is $31.53 and its 200-day moving average is $27.79. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $37.81. The firm has a market capitalization of $6.86 billion, a PE ratio of -15.06 and a beta of 1.07.

Analysts Set New Price Targets

BBIO has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Scotiabank raised their price objective on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 12th. Evercore ISI upped their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, December 23rd. Finally, Bank of America raised their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.08.

Institutional Investors Weigh In On BridgeBio Pharma

A number of hedge funds have recently made changes to their positions in BBIO. GF Fund Management CO. LTD. bought a new stake in BridgeBio Pharma during the 4th quarter worth approximately $109,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of BridgeBio Pharma by 1.1% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock worth $104,285,000 after buying an additional 40,000 shares in the last quarter. Woodline Partners LP grew its position in shares of BridgeBio Pharma by 132.9% during the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company’s stock worth $60,684,000 after buying an additional 1,261,772 shares during the period. Zimmer Partners LP bought a new stake in shares of BridgeBio Pharma in the 4th quarter valued at $4,950,000. Finally, Tema Etfs LLC acquired a new position in shares of BridgeBio Pharma during the 4th quarter valued at $3,896,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.